Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Methotrexate × Clear all Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Phase 2 Completed
84 enrolled
1703/1801
Phase 3 Completed
431 enrolled 44 charts
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Phase 2 Completed
20 enrolled 16 charts
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Phase 2 Completed
202 enrolled 17 charts
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Phase 3 Completed
101 enrolled 28 charts
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
Phase 2 Completed
201 enrolled 12 charts
BMT CTN 0402
Phase 3 Completed
304 enrolled 20 charts
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1 Completed
14 enrolled
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Phase 2 Completed
76 enrolled 16 charts
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Phase NA Completed
18 enrolled 7 charts
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
Phase 2 Withdrawn
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
Phase NA Completed
876 enrolled
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Phase 2 Completed
279 enrolled 28 charts
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
12 enrolled 11 charts
CICLODECH
Phase 3 Terminated
3 enrolled
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
Phase 3 Completed
170 enrolled 7 charts
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
Phase 2 Completed
6 enrolled 3 charts
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Phase 2 Withdrawn
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 1 Completed
15 enrolled
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
Phase 1/2 Withdrawn
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
Phase 3 Completed
6 enrolled 6 charts
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Phase 2 Completed
24 enrolled 13 charts
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
Phase 2 Terminated
42 enrolled 8 charts
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia
Phase 3 Completed
100 enrolled